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Abstract
Background: Increased circulating levels of hemostatic factors as well as anemia have been associated with increased
risk of cardiovascular disease (CVD). Known associations between hemostatic factors and sequence variants at genes
encoding these factors explain only a small proportion of total phenotypic variation. We sought to confirm known
putative loci and identify novel loci that may influence either trait in genome-wide association and linkage analyses using
the Affymetrix GeneChip 100K single nucleotide polymorphism (SNP) set.
Methods: Plasma levels of circulating hemostatic factors (fibrinogen, factor VII, plasminogen activator inhibitor-1, von
Willebrand factor, tissue plasminogen activator, D-dimer) and hematological phenotypes (platelet aggregation, viscosity,
hemoglobin, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration) were
obtained in approximately 1000 Framingham Heart Study (FHS) participants from 310 families. Population-based
association analyses using the generalized estimating equations (GEE), family-based association test (FBAT), and
multipoint variance components linkage analyses were performed on the multivariable adjusted residuals of hemostatic
and hematological phenotypes.
Results: In association analysis, the lowest GEE p-value for hemostatic factors was p = 4.5*10-16 for factor VII at SNP
rs561241, a variant located near the F7 gene and in complete linkage disequilibrium (LD) (r2 = 1) with the Arg353Gln F7
SNP previously shown to account for 9% of total phenotypic variance. The lowest GEE p-value for hematological
phenotypes was 7*10-8 at SNP rs2412522 on chromosome 4 for mean corpuscular hemoglobin concentration. We
presented top 25 most significant GEE results with p-values in the range of 10-6 to 10-5 for hemostatic or hematological
phenotypes. In relating 100K SNPs to known candidate genes, we identified two SNPs (rs1582055, rs4897475) in
erythrocyte membrane protein band 4.1-like 2 (EPB41L2) associated with hematological phenotypes (GEE p < 10-3). In
linkage analyses, the highest linkage LOD score for hemostatic factors was 3.3 for factor VII on chromosome 10 around
15 Mb, and for hematological phenotypes, LOD 3.4 for hemoglobin on chromosome 4 around 55 Mb. All GEE and FBAT
association and variance components linkage results can be found at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007
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BMC Medical Genetics 2007, 8(Suppl 1):S12 http://www.biomedcentral.com/1471-2350/8/S1/S12Conclusion: Using genome-wide association methodology, we have successfully identified a SNP in complete LD with
a sequence variant previously shown to be strongly associated with factor VII, providing proof of principle for this
approach. Further study of additional strongly associated SNPs and linked regions may identify novel variants that
influence the inter-individual variability in hemostatic factors and hematological phenotypes.
Background
The relationship of hemostasis and thrombosis with
atherothrombotic cardiovascular disease has been exten-
sively studied in the past decades. Elevated circulating lev-
els of hemostatic factors, such as fibrinogen [1-3],
plasminogen activator inhibitor (PAI-1) [4,5], von Wille-
brand factor (vWF) [6], tissue plasminogen activator (tPA)
[4,5,7], factor VII (FVII) [8], and D-dimer [9,10] are linked
to the development of atherothrombosis and are risk
markers for coronary heart disease (CHD), stroke and
other cardiovascular disease (CVD) events.
In addition to coagulation proteins, the cellular and rheo-
logical components of circulating blood have been impli-
cated in CHD, stroke and peripheral arterial disease,
including hematological phenotypes such as hematocrit
(HCT), hemoglobin (Hgb), red blood cell count (RBCC)
and size, mean corpuscular volume (MCV) and mean cor-
puscular hemoglobin (MCH) [11,12], as well as measures
of platelet aggregation (induced by adenosine 5'-diphos-
phate (ADP), epinephrine (Epi) and collagen respec-
tively) [12,13], and viscosity [14,15].
Cis-acting sequence variants in the following genes –
fibrinogen-β (FGB), fibrinogen-α (FGA), fibrinogen-γ
(FGG), FVII (F7), and PAI-1 (SERPINE1) – have been
associated with corresponding levels of circulating hemo-
static factor. By comprehensively characterizing common
genetic variation at each of these loci, we have recently
clarified that cis-acting variants, in sum, explain a modest
proportion of phenotypic variation, ranging from 1% –
10% [16,17]. For hematological variables such as hemat-
ocrit and hemoglobin, sequence variation in the major
hemoglobin genes is well described to be associated with
anemias, such as beta- and alpha-thalassemia, and sickle
cell anemia [18-20].
Systematic searches for novel genes beyond the known
genetic determinants influencing these phenotypes have
been carried out using genome-wide linkage analyses with
microsatellite markers: Chromosome regions that may
harbor novel loci influencing fibrinogen, PAI-1 [21,22],
hematocrit, Hgb, RBCC, MCV and MCH [23,24], have
been identified. However, linkage scans with microsatel-
lite markers generally had low power to detect loci with
small effects, and lacked precision in localizing the loci;
thus, few novel loci have been identified.
The recent completion of a genome-wide scan using the
Affymetrix GeneChip Human Mapping 100K single
nucleotide polymorphism (SNP) set on participants in
the Framingham Heart Study offered the opportunity to
conduct a genome-wide association study (GWAS) and
linkage scan for variants that influence hemostatic factors
and hematological phenotypes.
Methods
Study participants and genotyping methods
The Framingham Heart Study design and the genotyping
of the Affymetrix GeneChip Human Mapping 100K SNP
set on Framingham Heart Study participants are detailed
in the overview of this project [25]. To avoid potential
bias due to genotyping artifacts, we limited the associa-
tion analyses to 70987 SNPs on autosomes with minor
allele frequency (MAF) ≥ 10%, genotyping call rate ≥ 80%,
and Hardy-Weinberg equilibrium test p-value ≥ 0.001.
Measurements of hemostatic factors and hematological 
phenotypes
Venous blood samples of Framingham Heart Study Off-
spring Cohort taken at the first and second examination
cycles (1971–1975, and 1979–1983) were used to meas-
ure Hgb, RBCC, MCV and MCH, and samples taken at the
fifth examination cycle (1991–1995) were used to meas-
ure all the hemostatic factors, platelet aggregation, D-
dimer, and viscosity. Fibrinogen was additionally meas-
ured at the sixth (1995–1998) and seventh (1998–2001)
examination cycles, and PAI-I antigen levels at the sixth
exam. Details of the assessment of hemostatic factor levels
have been described previously [17,26]. Plasma fibrino-
gen levels were measured using the Clauss method [27].
Plasma PAI-I antigen, tPA antigen, von Willebrand factor
and FVII antigen were assessed using enzyme-linked
immunosorbent assays.
The determination of hematological phenotypes has been
detailed previously. Platelet aggregation was performed
according to the method of Born [28]. The reagents used
were epinephrine, ADP and collagen. The percent extent
of aggregation in duplicate to epinephrine and ADP was
determined in varying concentrations (0.01 to 15 mmol/
L). For each subject, the aggregation response (yes/no)
was also tested to a fixed concentration of arachidonic
acid (5 mg/mL). The collagen lag time was measured in
response to 1.9 mmol/L collagen. Participants who werePage 2 of 11
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aggregation phenotypes as well as PAI-1 and tPA.
HCT was measured by the Wintrobe method [29]. Blood
was collected and spun at 5000 rpm for 20 minutes in a
balanced oxalate tube. The percent of total blood volume
that was due to red blood cells was determined visually
against a calibrated scale. MCV is the average volume of an
individual's red blood cells determined as the ratio of
HCT to RBCC. MCH is the average amount of hemo-
globin of an individual's red cell determined as the ratio
of Hgb to RBCC.
Statistical methods
Standardized multivariable adjusted residuals of the
hemostatic and hematological phenotypes were com-
puted and used in all the linkage and association analyses.
Covariates used in the adjustments were determined
based upon what has been reported in the literature as
potential risk factors for hemostatic factors or hematolog-
ical phenotypes. Hardy-Weinberg equilibrium was exam-
ined using an exact chi-square test statistic [30].
Association between each SNP and each hemostatic or
hematological phenotype was examined using a popula-
tion based association method via generalized estimating
equations (GEE) [31] and family-based association test
(FBAT) [32], assuming an additive genetic model. Vari-
ance components linkage analyses were conducted using
a subset of SNPs with pairwise r2 < 0.5. Details of both
association and linkage methods are described in the
overview of this project [25].
In secondary analyses, we combined the GEE association
tests results across multiple phenotypes that may share the
common pathway to reduce the type I error rates, and pos-
sibly detect SNPs of smaller effect sizes. We ranked SNPs
by the number of GEE test p-values less than 0.01, and
then by the geometric mean of the GEE test p-values. We
also examined the β coefficient from the GEE regression
that is the change in the phenotype in one standardized
deviation unit with an increment of a copy of the alpha-
betically second allele (for example, allele G for a SNP
with alleles A and G). This analysis was conducted for a
phenotype assessed using multiple measurement meth-
ods such as the platelet aggregation with ADP-, collagen-,
and Epi-induced platelet aggregation; or for a phenotype
with serial measurements such as fibrinogen level meas-
ured at examination cycles 5, 6 and 7.
We attempted to identify association of 100K SNPs in or
within 60 kilo base pairs (kbp) of selected candidate genes
previously reported to be associated with hemostatic fac-
tors or hematological phenotypes. For hemostatic factors
and platelet aggregation phenotypes, we included the fol-
Table 1: Description of hemostatic factors, hematological phenotypes, and covariates adjustment
Phenotype Number of adjusted 
phenotypes
Offsrping cohort 
exam cycles†
Sample size 
(min-max)
Covariates adjusted
Hemostatic factors:
fibrinogen 4 5, 6, 7 and average 986–1073 age (and its squared and cubic terms), sex, body mass 
index, prevalent cardiovascular disease, current cigarette 
smoking, hypertension treatment, systolic blood 
pressure, diastolic blood pressure, estrogen therapy 
(women only), alcohol intake, triglycerides, diabetes, 
total cholesterol, and the ratio of total cholesterol to 
high-density lipoprotein cholesterol.
PAI-1 3 5, 6 and average 788–1037
tPA 1 5 786
vWF 1 5 883
FVII 1 5 886
D-dimer 1 5 987
Hematological and 
rheological phenotypes
platelet aggregation (ADP-
induced)
1 5 724
platelet aggregation (collagen-
induced)
1 5 702
platelet aggregation (Epi-induced) 1 5 719
Viscosity 1 5 832
Hgb 3 1, 2, and average 903–1066 age, sex, height, weight, high-density lipoprotein 
cholesterol, total serum protein, alcohol intake, 
triglycerides, and current cigarette smoking
RBCC 3 1, 2, and average 903–1062
MCH 3 1, 2, and average 903–1062
Hematocrit* 3 1, 2, and average 903–1062
MCV 3 1, 2, and average 903–1062
WBC* 3 1, 2, and average 903–1062
*Results for these two phenotypes are not reported in this manuscript. The complete results of all the phenotypes listed above can be found at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007Page 3 of 11
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cluster (FGB, FGA, FGG), SERPINE1, plasminogen activa-
tor-tissue (PLAT), vWF and integrin beta 3 (ITGB3). For
hematological phenotypes excluding platelet aggregation,
we included erythropoietin receptor (EPOR), erythropoi-
etin (EPO), erythrocyte membrane protein band 4.1-like
2 (EPB41L2), Kruppel-like factor 1(KLF1), heme binding
protein 2 (HEBP2), the hemoglobin gene clusters on chro-
mosome 11: hemoglobin-β chain complex (HBB), hemo-
globin-δ (HBD), hemoglobin-γ A (HBG1), hemoglobin-γ
G (HBG2), hemoglobin-ε 1 (HBE1), and the hemoglobin
gene clusters on chromosome 16: hemoglobin-α 1
(HBA1), hemoglobin-α 2 (HBA2), hemoglobin-μ (HBM).
Results
Table 1 displays the hemostatic and hematological phe-
notypes analyzed in this study, as well as the number of
individuals, examination cycles, and covariates used in
multivariable models. The sample size ranged from 702 to
1073. Traits measured at multiple examinations were ana-
lyzed using multivariable adjusted residuals from each
examination measure, and also the average of all the mul-
tivariable adjusted residuals from individual examination
cycles.
Among individuals who were included in the genotyping
and had at least one hemostatic factor or platelet aggrega-
tion phenotype measured at examination cycle five, 52%
were women, mean age was 52 years, and 6% had preva-
lent CVD. Among individuals who were included in the
genotyping and had at least one hematological phenotype
measured at examination cycle one or two, 52% were
women, with a mean age over the two examinations of 36
years, and 2% had prevalent CVD.
Association between SNPs and hemostatic and 
hematological phenotypes
We report the 25 SNPs with lowest GEE association test p-
values in Table 2 for hemostatic factors, and in Table 3 for
hematological phenotypes. The lowest GEE p-value
(4.5*10-16) for hemostatic factors was obtained from the
test of association between circulating levels of FVII and
rs561241; this SNP resides near the F7 gene on chromo-
some 13 and is in complete linkage disequilibrium (LD)
(r2 = 1) with the Arg353Gln F7 SNP (rs6046) we previ-
ously reported to account for 9% of total phenotypic var-
iance [16]. The lowest GEE p-value (6.9*10-8) for
hematological phenotypes was obtained in the test of
association between MCH and rs1397048 on chromo-
some 11 near the olfactory receptors, olfactory receptor,
family 5, subfamily AP, member 2 (OR5AP2), olfactory
receptor, family 5, subfamily AR, member 1 (OR5AR1),
olfactory receptor, family 9, subfamily G, member
1(OR9G1) and olfactory receptor, family 9, subfamily G,
Table 2: The 25 SNPs with lowest GEE association test p-values with hemostatic factors measured at exam 5
Phenotype* SNP MAF CHR Physical Position (bp)† GEE p-val (Rank)†† FBAT p-val††† Genes within 60 kb
Fibrinogen rs6683832 0.41 1 62,988,925 5.6 × 10-5(4) 3.4 × 10-2 APG4C
Fibrinogen rs4861952 0.11 4 182,696,179 3.5 × 10-5(24) 8.2 × 10-3
Fibrinogen rs10506540 0.12 12 65,699,364 2.2 × 10-5(16) 3.3 × 10-2
Fibrinogen rs974673 0.15 14 33,550,265 3.1 × 10-5(19) 1.3 × 10-3
FVII rs966321 0.47 1 4,225,577 7.6 × 10-6(6) 4.5 × 10-2
FVII rs1245072 0.17 1 69,827,777 1.8 × 10-5(13) 7.5 × 10-3 LRRC7
FVII rs2362932 0.24 1 242,240,325 2.4 × 10-5(17) 1.5 × 10-2 SMYD3
FVII rs10496112 0.30 2 64,535,384 3.3 × 10-5(23) 7.4 × 10-3 HSPC159
FVII rs1001254 0.13 3 7,909,333 2.0 × 10-5(14) 2.0 × 10-2
FVII rs4591494 0.19 3 7,957,827 9.2 × 10-6(7) 1.2 × 10-4
FVII rs10488360 0.30 7 4,184,450 7.2 × 10-6(5) 9.3 × 10-3
FVII rs727435 0.13 9 80,809,022 9.6 × 10-6(8) 2.8 × 10-2
FVII rs7938734 0.31 11 49,834,857 3.2 × 10-5(21) 7.0 × 10-2
FVII rs561241 0.12 13 112,808,035 4.5 × 10-16(1) 3.4 × 10-4 MCF2L; AB116074; AK092739; AK123267; 
AB002360; F7; CR603372; F10; PROZ
PAI1 rs10490733 0.14 2 137,872,229 3.2 × 10-5(22) 2.4 × 10-2
PAI1 rs4460176 0.29 5 109,524,859 3.1 × 10-6(3) 7.6 × 10-2
tPA rs10493485 0.29 1 71,783,150 1.6 × 10-6(2) 1.1 × 10-3 BC036771; NEGR1
tPA rs10494076 0.32 1 108,050,369 3.1 × 10-5(20) 2.3 × 10-2 VAV3
tPA rs2029637 0.25 3 113,404,510 1.3 × 10-5(10) 6.1 × 10-2 SLC9A10
tPA rs953377 0.28 6 23,998,670 1.5 × 10-5(11) 3.4 × 10-2
vWF rs9295740 0.14 6 27,797,481 2.8 × 10-5(18) 5.7 × 10-3
vWF rs202906 0.12 6 28,119,631 2.1 × 10-5(15) 1.1 × 10-1 ZNF165
vWF rs708356 0.35 12 128,998,794 1.5 × 10-5(12) 2.4 × 10-2 AK127723
vWF rs1954971 0.38 18 26,633,241 1.0 × 10-5(9) 1.6 × 10-2
vWF rs7319671 0.30 13 36,923,224 3.6 × 10-5(25) 1.1 × 10-2
* All the phenotypes reported here were multivariable adjusted residuals from the measurements obtained at exam cycle 5.
†Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
††P-value from GEE genotype association test and rank of the GEE p-values in ascending order.
†††P-value from family-based association test using the FBAT program.Page 4 of 11
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ciation test p-values are presented in Additional file 1,
Table A1 and Table A2, respectively.
Linkage results
Maximum multipoint LOD scores greater than 2 and the
1.5-LOD support intervals around the maximum LOD
scores are presented in Table 4. The highest LOD score for
hemostatic factors was 3.3 for factor VII at approximately
15 Mb on chromosome 10. The highest LOD for hemato-
logical phenotypes was 3.4 for Hgb at approximately 55
Mb on chromosome 4.
Combining association tests across multiple phenotypes
The top 10 SNPs with most number of p-values < 0.01 and
lowest mean p-values are reported in Tables 5 and 6 for
platelet aggregation phenotypes and fibrinogen levels
respectively. The top ranked SNP for platelet aggregation
was rs10500631 on chromosome 11 located near an
olfactory gene cluster. The p-values of the GEE association
test for ADP-, collagen- and epinephrine-induced platelet
aggregation levels with this SNP were all less than 0.01,
with average p-value 0.007 over the three tests. The range
of the regression coefficients was 0.19–0.24, indicating
the effect size was consistently estimated across the three
phenotypes.
For fibrinogen, the top ranked SNP was rs4861952 on
chromosome 4, which was also listed in the Table 2 as one
of the 25 most significantly associated SNPs with hemo-
static factors. This SNP was consistently associated with
fibrinogen levels across three examination cycles with
effect size ranging from -0.28 to -0.17.
Association of SNPs in known candidate genes
100K SNPs residing in or near known candidate genes for
hemostatic factors are presented in Table 7. Among the
candidate genes for hemostatic factors, no 100K SNP was
in or within 60 kb of PLAT. Only SNPs in or near the rest
of the candidate genes (F7, FGG, FGA, FGB, ITGB3,
SERPINE1 and vWF) are presented. Among all these asso-
ciations, three reached nominal significance (p-value 
< 0.05): rs561241 for factor VII, and rs6950982 and
rs6956010 for PAI-1.
Among the candidate genes for hematological traits, no
100K SNP was in or within 60 Kb of EPOR, EPO, KLF1,
HBA1, HBA2, HBM. For the rest of the candidate genes,
associations between hematological phenotypes and
100K SNPs in/near EPB41L2, the beta hemoglobin gene
cluster on chromosome 11 (HBB, HBD, HBG1, HBG2,
HBE1), and HEBP2 are presented in Table 8. The most sig-
nificant associations were SNP rs1582055 near EPB41L2
Table 3: The 25 SNPs with lowest GEE association tests p-values with hematological phenotypes
Phenotype* SNP MAF CHR Physical Position (bp)† GEE Pval (Rank)†† FBAT Pval††† Genes within 60 Kb
Hgb rs4133289 0.19 1 156,267,010 1.6 × 10-7(2) 6.0 × 10-4 OR10J1; OR10J5
Hgb rs1510107 0.41 2 53,071,788 1.0 × 10-5(17) 2.2 × 10-3
Hgb rs1160297 0.43 2 53,148,971 1.0 × 10-6(4) 8.3 × 10-4
Hgb rs2357013 0.45 2 53,177,780 6.1 × 10-6(14) 1.3 × 10-3
Hgb rs7844723 0.45 8 122,977,684 2.1 × 10-6(5) 2.6 × 10-3
MCH rs1829883 0.41 5 98,809,002 5.8 × 10-6(11) 1.4 × 10-2
MCH rs1200821 0.47 10 37,599,586 5.9 × 10-6(13) 1.0 × 10-1 ANKRD30A
MCH rs1397048 0.40 11 56,222,675 6.9 × 10-8(1) 1.0 × 10-2 OR5AP2; OR5AR1; OR9G1; OR9G4
platelet aggregation (ADP-induced) rs10493895 0.19 1 97,983,247 1.6 × 10-5(23) 4.5 × 10-2 BC064027; DPYD
platelet aggregation (ADP-induced) rs10484128 0.15 14 97,712,325 5.8 × 10-6(12) 1.3 × 10-3
platelet aggregation (collagen-induced) rs848523 0.42 2 36,659,307 2.1 × 10-5(24) 4.3 × 10-1 CRIM1
platelet aggregation (collagen-induced) rs565229 0.10 11 121,694,675 3.7 × 10-6(6) 2.6 × 10-2
platelet aggregation (collagen-induced) rs10506458 0.13 12 61,731,359 4.5 × 10-6(9) 1.1 × 10-4
platelet aggregation (Epi-induced) rs6811964 0.11 4 158,143,059 1.3 × 10-5(20) 5.5 × 10-2 PDGFC
platelet aggregation (Epi-induced) rs1958208 0.32 14 81,194,793 1.1 × 10-5(18) 7.0 × 10-1
platelet aggregation (Epi-induced) rs10502583 0.17 18 28,011,131 1.1 × 10-5(19) 1.1 × 10-2 RNF138; MEP1B
RBCC rs9253 0.18 1 37,627,906 4.2 × 10-6(7) 1.1 × 10-5 FLJ11730; BC016328
RBCC rs10489087 0.13 4 13,470,685 4.5 × 10-6(8) 9.6 × 10-4
RBCC rs636864 0.21 6 149,567,299 6.3 × 10-6(15) 1.3 × 10-4
RBCC rs727979 0.14 6 149,635,613 7.5 × 10-6(16) 2.6 × 10-5 MAP3K7IP2
RBCC rs6108011 0.28 20 7,500,504 5.8 × 10-6(10) 7.0 × 10-2
Viscosity rs10490258 0.11 2 40,717,605 1.5 × 10-5(21) 2.9 × 10-2
Viscosity rs1359339 0.18 6 18,606,507 2.2 × 10-5(25) 2.3 × 10-2 IBRDC2
Viscosity rs10485968 0.20 7 81,108,037 1.6 × 10-5(22) 3.0 × 10-3
Viscosity rs7159841 0.21 14 46,933,585 2.1 × 10-7(3) 2.0 × 10-1 MAMDC1
* For Hgb, MCH and RBCC reported here, multivariable adjusted residuals from average of measurements over exam cycles 1 and 2 were used; for all 
platelet aggregation phenotypes, and viscosity reported here, multivariable adjusted residuals from measurements at examination cycle 5 were used.
†Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
††P-value from GEE genotype association test and rank of the GEE p-values in ascending order.
†††P-value from family-based association test using the FBAT program.Page 5 of 11
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Table 5: Top 10 ranked SNPs in combining GEE association tests of ADP-induced, Collagen-induced and Epi-induced platelet 
aggregation levels
GEE P-value of individual 
phenotypes
SNP MAF CHR Physical 
Position (bp)*
Mean GEE 
p-value
Range of Beta Coeffi-
cient† (min, max)
Number of 
Phenotypes with 
GEE P-value < 0.01
Gene 
within 60 
Kb
ADP Collagen Epi
rs10500631 0.13 11 4,882,639 6.6 × 10-3 0.19 0.24 3 OR51S1; 
OR51T1; 
OR51A7; 
OR51G2; 
OR51G1; 
OR51A4; 
OR51A2
9.7 × 10-3 7.8 × 10-3 3.8 × 10-3
rs930323 0.18 1 221,172,525 1.9 × 10-3 -0.26 -0.16 2 CNIH3 3.8 × 10-2 1.6 × 10-3 1.2 × 10-4
rs7033457 0.25 9 7,383,934 2.6 × 10-3 0.15 0.24 2 2.5 × 10-3 3.7 × 10-2 2.0 × 10-4
rs2974490 0.11 5 113,433,775 2.7 × 10-3 0.07 0.28 2 4.2 × 10-1 8.7 × 10-5 5.2 × 10-4
rs10517543 0.13 4 40,332,115 3.2 × 10-3 0.13 0.27 2 AF262323; 
FLJ20273
5.8 × 10-3 1.0 × 10-1 5.2 × 10-5
rs2916601 0.13 5 89,556,637 3.5 × 10-3 0.11 0.29 2 9.7 × 10-2 3.2 × 10-4 1.4 × 10-3
rs4350297 0.18 10 106,463,038 3.9 × 10-3 -0.24 -0.10 2 SORCS3 3.5 × 10-4 1.0 × 10-1 1.7 × 10-3
rs7956194 0.42 12 108,340,545 4.3 × 10-3 0.09 0.20 2 FLJ37587; 
KCTD10; 
BC040062; 
AK056912; 
BC051266; 
UBE3B
3.6 × 10-3 1.1 × 10-1 2.0 × 10-4
* Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
†β coefficient is the change in the phenotype in one standardized deviation unit with an increment of a copy of the alphabetically higher allele.
Table 4: Maximum LOD scores (≥2) on each chromosomes for hemostatic factors and hematological phenotypes
Phenotype* SNP CHR Physical Position (bp)† LOD 1.5 LOD Support Interval
Fibrinogen rs1273819 2 227,307,918 2.4 221,455,139 234,213,322
FVII rs1542535 3 138,548,560 2.8 128,478,856 147,720,726
FVII rs2400107 10 15,113,999 3.3 13,834,912 21,013,729
PAI1 143xd8 8 2,117,752 2.3 181,076 5,519,520
vWF rs10514670 3 18,544,296 2.1 9,261,438 25,964,778
platelet aggregation (ADP-induced) rs4148751 7 86,787,804 2.0 81,841,699 94,233,832
platelet aggregation (collagen-induced) rs17310225 X 41,973,417 2.1 30,937,095 81,367,217
Hgb rs2412522 4 54,779,471 3.4 41,552,790 57,899,713
Hgb rs10514838 9 120,826,350 2.5 113,537,965 133,903,932
MCVavg12 rs38993 7 153,013,905 2.2 149,613,755 154,729,817
MCVavg12 rs9299952 11 19,075,037 3.3 12,241,666 21,560,867
MCVavg12 rs10522006 X 32,347,187 2.3 27,553,388 40,183,712
RBCC rs956275 4 57,108,334 2.5 44,437,719 74,935,678
RBCC rs2023048 6 162,441,307 2.9 156,253,205 165,513,097
RBCC rs10500769 11 12,975,794 3.2 9,335,581 15,231,734
RBCC rs10500770 11 13,053,050 3.2 9,335,581 15,231,734
RBCC rs2178692 12 6,706,312 2.8 4,817,859 9,212,944
RBCC rs10498633 14 91,996,705 2.6 74,270,406 93,717,052
RBCC GATA27A03 15 100,152,332 2.3 98,566,644 100,152,332
RBCC rs2271090 17 76,861,200 2.3 73,915,579 78,166,561
RBCC rs486633 18 555,760 3.3 156,277 4,009,209
RBCC rs20037 22 27,802,395 2.2 25,095,430 42,711,182
* For Hgb, MCH and RBCC reported here, multivariable adjusted residuals from average of measurements over exam cycles 1 and 2 were used; for 
all platelet aggregation phenotypes, fibrinogen, FVII, PAI1, vWF reported here, multivariable adjusted residuals from measurements at examination 
cycle 5 were used.
†Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
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RBCC (p = 3.9 × 10-4); SNP rs4897475 with hematocrit (p
= 1.6 × 10-4) and Hgb (p = 6.0 × 10-4).
Discussion
We conducted a GWAS and a genome-wide linkage anal-
yses for hemostatic factors and hematological phenotypes
measured in Framingham Heart Study Offspring partici-
pants. We identified a highly significant association
between factor VII level and SNP rs561241 in complete
LD with the F7 SNP rs6046 (Arg353Gln) previously dem-
onstrated to explain about 9% of total phenotypic varia-
tion. This association is significant after Bonferroni
correction for multiple testing (we used a conservative α =
5 × 10-8), and confirms the strong association at this locus
that has previously been reported by us and others. This
SNP was also significant (p-value = 3.4 × 10-4) at a nomi-
nal α level 0.05 for FBAT and linkage test (LOD = 1.8, p-
value = 0.002), but not after Bonferroni correction. That
may be explained by the well known fact that FBAT and
linkage test are less powerful than population-based asso-
ciation tests.
FBAT lacks power to detect variants that explain small pro-
portion of variance for this study. It is difficult to distin-
guish true positives from false ones among FBAT results
because it was evident that few 100K SNPs explain a large
proportion of variance for hemostatic factors or hemato-
logical phenotypes. Given that there is no evidence for
major population substructure in FHS [33] and there is
greater power from use of GEE testing, we emphasize our
population-based GEE analysis results in this report. Link-
age analyses have the same problem of low power to
detect small effects. However, a linkage peak can be
caused by loci in linkage but not in LD with the SNPs, or
by several loci of small effects in the region. Thus linkage
peaks deserve additional attention. For example, we iden-
tified a linkage peak on chromosome 10 for multivariate
adjusted factor VII. The SNP underneath the peak is
rs2400107. However, the GEE association p-value was
0.52. This could occur because rs2400107 was linked but
not in LD with the disease locus (loci) under the peak, or
because this linkage peak was caused by several loci of
small effects, or this peak was a false positive. Therefore, a
more careful examination of the association results of
SNPs under the linkage peak along with potentially addi-
tional genotyping may be needed to confirm the linkage
results.
Among the SNPs with top GEE p-values in single pheno-
type or multiple phenotypes analyses, only a few resided
near genes that were known for a likely role in hemostasis
and thrombosis and hematological biology. For hemo-
static factors, the cis-acting SNP rs561241 near F7 gene
was associated with factor. For hematological phenotypes,
we identified rs6811964 near PDGFC, platelet derived
growth factor-C. It has been shown that PDGFC highly
expressed in vascular smooth muscle cells, renal mesang-
ial cells and platelets, and was likely involved in platelet
biology [34]. This SNP was found associated with Epi-
induced platelet aggregation (P = 10-5, Table 3), with
ADP-induced platelet aggregation at nominal significance
(P = 0.02), and with collagen-induced platelet aggregation
at borderline nominal significance (P = 0.08). Other asso-
ciations were found with SNPs in genes not clearly related
to the phenotypes, or with SNPs that are not in known
genes. These associations, together with other findings
from this GWAS, must be viewed as hypotheses that war-
rant further testing in other cohorts.
Although we only summarized results for multivariable
adjusted phenotype, we have also conducted linkage and
association analyses for age-sex adjusted phenotypes. It is
possible that the effects of some loci may be mediated
through the covariates included in multivariable adjust-
ment, and thus only associated with age and sex adjusted
Table 6: Top 10 ranked SNPs in combining GEE association tests of fibrinogen levels measured at examination cycles 5, 6 and 7
SNP MAF CHR Physical 
Position (bp)*
mean 
GEE 
P-value
Range of β 
Coefficients† 
(min, max)
Number of 
Phenotypes with 
GEE P-value < 0.01
Gene within 60 
Kb
GEE P-value of individual phenotypes
Exam 5 Exam 6 Exam 7
rs4861952 0.11 4 182,696,179.00 4.9 × 10-4 -0.28 -0.17 3 3.5 × 10-5 9.2 × 10-3 3.6 × 10-4
rs1869733 0.15 8 63,970,954.00 5.5 × 10-4 -0.23 -0.16 3 FLJ39630 6.7 × 10-5 4.1 × 10-3 6.1 × 10-4
rs9317390 0.47 13 63,625,531.00 6.5 × 10-4 0.13 0.17 3 3.8 × 10-3 1.9 × 10-4 3.8 × 10-4
rs1561478 0.15 4 61,317,252.00 7.3 × 10-4 0.15 0.22 3 3.0 × 10-4 1.6 × 10-4 8.6 × 10-3
rs277330 0.16 5 53,489,351.00 1.1 × 10-3 -0.22 -0.16 3 ARFRP2 1.5 × 10-3 1.9 × 10-4 4.1 × 10-3
rs1649053 0.41 10 59,991,493.00 1.2 × 10-3 0.13 0.18 3 2.8 × 10-3 5.8 × 10-3 1.0 × 10-4
rs2175271 0.09 15 34,097,057.00 1.5 × 10-3 -0.26 -0.20 3 6.5 × 10-3 3.1 × 10-4 1.8 × 10-3
rs9323656 0.06 14 77,394,323.00 1.5 × 10-3 -0.31 -0.27 3 ADCK1; AK096919 1.2 × 10-3 2.5 × 10-3 1.3 × 10-3
rs1423741 0.42 16 59,874,592.00 1.8 × 10-3 -0.17 -0.11 3 7.6 × 10-4 9.4 × 10-3 7.6 × 10-4
rs10497881 0.32 2 205,818,470.00 2.2 × 10-3 0.14 0.17 3 ALS2CR19 4.8 × 10-4 5.0 × 10-3 4.5 × 10-3
* Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
†β coefficient is the change in the phenotype in one standardized deviation unit with an increment of a copy of the alphabetically higher allele.Page 7 of 11
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with age and sex adjusted hemostatic factors or hemato-
logical phenotypes with a GEE p-value equal or less than
10-5, 28 SNPs had a GEE p-value greater than 10-5 with
multivariable adjusted phenotypes. However, no age and
sex adjusted GEE p-value for the 28 SNPs reached
genome-wide significance (p-value < 5 × 10-8), and no
new highly plausible candidate genes resided within 60
Kb of these SNPs. The full disclosure results of all analyses,
including the age-sex adjusted analyses, can be viewed at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007.
There are some limitations to this study. The participants
are Caucasian and thus the results may not be generaliza-
ble to other racial groups. The study sample size was rela-
tively small, and as such, we may have insufficient power
to detect small effects. To avoid worsening the multiple
testing problem, we performed only sex-pooled and not
sex-specific analyses. There may be some SNPs that are
associated with some phenotypes only in female or male
undetected in the current study. The advantages of this
study are that we had family data, which enabled us to
also apply family-based association tests that are robust to
population admixture, and linkage analyses that can
detect loci not in LD but in linkage with any 100K SNP.
The study subjects were recruited without regarding to
their phenotypic values, which makes the analyses of mul-
tiple phenotypes possible without the need to correct
ascertainment bias.
Finally, compared with studies focused only on SNPs
within candidate genes, GWAS approaches are unbiased
and as such they have the advantage of detecting novel
genes or confirming genes that are not well-known to
have an influence on a phenotype. However, since the cur-
rent GWAS uses only a subset of all the SNPs in HapMap
[35], it may miss some genes due to lack of coverage. For
the same reason, GWAS data usually are not enough to
study a candidate gene comprehensively. To understand
the roles played by each SNP in a candidate gene, addi-
tional genotyping, and single-SNP and haplotype analyses
are needed. A large GWAS involving more than 550,000
SNPs in more than 9000 participants of FHS will be avail-
Table 7: Association between SNPs in/near known hemostatic candidate genes, and the corresponding phenotypes
Candidate Gene SNP CHR Physical Position (bp)* MAF Position to
Gene
Function Phenotype† GEE
Association
Pvalue
F7 rs561241 13 112,808,035 0.12 NEAR unknown FVII, exam 5 4.5 × 10-16
FGG rs2066864 4 155,883,300 0.19 IN intron Fibrinogen, average 0.239
FGG rs2066864 4 155,883,300 0.19 IN intron Fibrinogen, exam 5 0.711
FGG rs2066864 4 155,883,300 0.19 IN intron Fibrinogen, exam 6 0.095
FGG rs2066864 4 155,883,300 0.19 IN intron Fibrinogen, exam 7 0.586
FGG rs1074801 4 155,933,889 0.49 NEAR unknown Fibrinogen, average 0.667
FGG rs1074801 4 155,933,889 0.49 NEAR unknown Fibrinogen, exam 5 0.898
FGG rs1074801 4 155,933,889 0.49 NEAR unknown Fibrinogen, exam 6 0.521
FGG rs1074801 4 155,933,889 0.49 NEAR unknown Fibrinogen, exam 7 0.608
ITGB3 rs4525555 17 42,692,948 0.31 IN intron Platelet Aggregation, ADP, exam 5 0.231
ITGB3 rs4525555 17 42,692,948 0.31 IN intron Platelet Aggregation, Collagen, exam 5 0.375
ITGB3 rs4525555 17 42,692,948 0.31 IN intron Platelet Aggregation, epinephrine, exam 5 0.292
ITGB3 rs10514919 17 42,697,128 0.24 IN intron Platelet Aggregation, ADP, exam 5 0.495
ITGB3 rs10514919 17 42,697,128 0.24 IN intron Platelet Aggregation, Collagen, exam 5 0.331
ITGB3 rs10514919 17 42,697,128 0.24 IN intron Platelet Aggregation, epinephrine, exam 5 0.302
ITGB3 rs2015729 17 42,709,492 0.36 IN intron Platelet Aggregation, ADP, exam 5 0.326
ITGB3 rs2015729 17 42,709,492 0.36 IN intron Platelet Aggregation, Collagen, exam 5 0.919
ITGB3 rs2015729 17 42,709,492 0.36 IN intron Platelet Aggregation, epinephrine, exam 5 0.963
SERPINE1 rs6950982 7 100,360,038 0.18 NEAR unknown PAI1, average 0.187
SERPINE1 rs6950982 7 100,360,038 0.18 NEAR unknown PAI1, exam 5 0.035
SERPINE1 rs6950982 7 100,360,038 0.18 NEAR unknown PAI1, exam 6 0.688
SERPINE1 rs6956010 7 100,360,470 0.19 NEAR unknown PAI1, average 0.218
SERPINE1 rs6956010 7 100,360,470 0.19 NEAR unknown PAI1, exam 5 0.053
SERPINE1 rs6956010 7 100,360,470 0.19 NEAR unknown PAI1, exam 6 0.740
VWF rs917858 12 5,952,199 0.32 IN intron wVW, exam 5 0.398
VWF rs917859 12 5,952,374 0.32 IN intron wVW, exam 5 0.413
VWF rs2239138 12 5,952,819 0.32 IN intron wVW, exam 5 0.487
VWF rs216901 12 5,975,129 0.48 IN intron wVW, exam 5 0.297
VWF rs216903 12 5,975,760 0.48 IN intron wVW, exam 5 0.316
VWF rs216904 12 5,976,279 0.34 IN intron wVW, exam 5 0.584
* Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
†'NEAR' means within 60 kb to a gene; 'IN' means within a gene.
††Phenotypes are multivariate adjusted residuals.Page 8 of 11
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for detection of smaller effects for the hemostatic and
hematological phenotypes.
Conclusion
In summary, we have tested for association and linkage
using the Affymetrix 100K SNPs and a set of hemostatic
factor and hematological phenotypes. We have confirmed
a previously reported association, providing proof of prin-
ciple (a "positive control") for the GWAS approach. Our
results provide a set of hypotheses that warrant testing in
additional studies.
Abbreviations
ADP = adenosine 5'-diphosphate; bp = base pair(s); CHD
= coronary heart disease; CVD = cardiovascular disease;
CHR = chromosome; EPB41L2 = erythrocyte membrane
protein band 4.1-like 2; EPO = erythropoietin; EPOR =
erythropoietin receptor; FBAT = family-based association
test; FGB = fibrinogen-β; FGA = fibrinogen-α; FGG =
fibrinogen-γ; FHS = Framingham Heart Study; FVII = fac-
tor VII; GAW = Genetic Analysis Workshop; GEE = gener-
alized estimating equations; GWAS = genome-wide
association study; HBA1 = hemoglobin-α 1; HBA2 =
hemoglobin-α 2; HBB = hemoglobin-β chain complex;
HBD = hemoglobin-δ; HBE1 = hemoglobin-ε 1; HBG1 =
hemoglobin-γ A; HBG2 = hemoglobin-γ G; HBM = hemo-
globin-μ; HCT = hematocrit; HEBP2 = heme binding pro-
tein 2; Hgb = hemoglobin; ITGB3 = integrin, beta 3
(platelet glycoprotein IIIa, antigen CD61); kb = kilo base
pairs (=1,000 bp); KLF1 = Kruppel-like factor 1; LD = link-
age disequilibrium; MAF = minor allele frequency; MCV =
mean corpuscular volume; MCH = mean corpuscular
hemoglobin; Mb = mega base pairs (=1,000,000 bp);
OR5AP2 = olfactory receptor, family 5, subfamily AP,
member 2; OR5AR1 = olfactory receptor, family 5, sub-
family AR, member 1; OR9G1 = olfactory receptor, family
9, subfamily G, member 1; OR9G4 = olfactory receptor,
family 9, subfamily G, member 4; PAI-1 = plasminogen
activator inhibitor; PDGFC = platelet derived growth fac-
tor-C; RBCC = red blood cell count; SERPINE1 = serpin
peptidase inhibitor, clade E, member 1; SNP = single
Table 8: Association between hematological phenotypes and SNPs in/near known candidate genes
GEE Association Test P-values††
Candidate Gene SNP CHR Physical Position
(bp)*
MAF Position
to Gene†
Function Hematocrit Hgb MCH MCV RBCC
EPB41L2 rs7741731 6 131,152,063 0.17 NEAR unknown 0.488 0.326 0.847 0.549 0.163
EPB41L2 rs1582055 6 131,186,056 0.3 NEAR unknown 7.7 × 10-5 2.9 × 10-4 0.427 0.762 3.9 × 10-4
EPB41L2 rs1413753 6 131,192,197 0.34 NEAR intron 0.003 0.007 0.691 0.730 0.007
EPB41L2 rs1413754 6 131,192,319 0.3 NEAR intron 0.242 0.158 0.561 0.039 0.016
EPB41L2 rs4075265 6 131,208,150 0.33 IN untranslated 0.001 0.004 0.470 0.506 0.002
EPB41L2 rs915171 6 131,226,607 0.26 IN intron 0.712 0.486 0.355 0.232 0.273
EPB41L2 rs9285468 6 131,233,823 0.33 IN intron 0.003 0.005 0.437 0.921 0.022
EPB41L2 rs6938586 6 131,251,097 0.18 IN intron 0.878 0.511 0.578 0.661 0.951
EPB41L2 rs3777442 6 131,251,481 0.48 IN intron 0.017 0.124 0.834 0.568 0.044
EPB41L2 rs4897472 6 131,254,831 0.49 IN intron 0.002 0.022 0.972 0.551 0.009
EPB41L2 rs4897475 6 131,274,643 0.28 IN intron 1.6 × 10-4 6.0 × 10-4 0.633 0.485 0.011
EPB41L2 rs1334689 6 131,275,701 0.31 IN intron 0.001 0.005 0.703 0.639 0.020
EPB41L2 rs7748468 6 131,297,742 0.3 IN intron 0.002 0.005 0.616 0.956 0.009
EPB41L2 rs2105250 6 131,325,875 0.28 IN unknown 0.013 0.002 0.050 0.696 0.076
EPB41L2 rs9321263 6 131,340,606 0.33 IN unknown 0.461 0.137 0.188 0.095 0.056
EPB41L2 rs1811949 6 131,340,872 0.32 IN unknown 0.511 0.210 0.176 0.119 0.076
EPB41L2 rs9321265 6 131,345,926 0.14 IN unknown 0.985 0.909 0.734 0.941 0.896
EPB41L2 rs7761311 6 131,352,801 0.37 IN unknown 0.986 0.553 0.202 0.066 0.143
EPB41L2 rs1412540 6 131,368,085 0.24 IN unknown 0.006 0.006 0.356 0.725 0.008
EPB41L2 rs6907809 6 131,374,355 0.21 IN unknown 0.739 0.928 0.153 0.049 0.281
EPB41L2 rs951251 6 131,432,905 0.15 NEAR unknown 0.851 0.789 0.419 0.009 0.075
HBB, HBD rs4128714 11 5,151,240 0.25 NEAR unknown 0.557 0.402 0.345 0.175 0.431
HBB, HBD, HBG1, HBG2, HBE1 rs2105819 11 5,216,303 0.46 NEAR unknown 0.007 0.039 0.128 0.027 0.463
HBB, HBD, HBG1, HBG2, HBE1 rs968856 11 5,217,152 0.47 NEAR unknown 0.013 0.049 0.202 0.016 0.576
HBB, HBD, HBG1, HBG2, HBE1 rs10488676 11 5,225,373 0.48 NEAR unknown 0.051 0.134 0.174 0.047 0.735
HBB, HBD, HBG1, HBG2, HBE1 rs10488675 11 5,254,606 0.27 NEAR unknown 0.050 0.180 0.798 0.077 0.920
HBG1, HBG2, HBE1 rs3898916 11 5,284,996 0.38 NEAR unknown 0.089 0.165 0.353 0.260 0.367
HEBP2 rs10499199 6 138,811,539 0.16 NEAR intron 0.503 0.585 0.557 0.412 0.972
HEBP2 rs10499200 6 138,813,645 0.16 NEAR intron 0.706 0.742 0.535 0.382 0.793
HEBP2 rs10499201 6 138,818,107 0.16 NEAR intron 0.633 0.725 0.487 0.414 0.897
HEBP2 rs6902919 6 138,819,479 0.21 NEAR intron 0.789 0.977 0.225 0.148 0.541
HEBP2 rs6926204 6 138,820,053 0.16 NEAR intron 0.887 0.979 0.429 0.381 0.660
* Physical position is in base pair (bp) and based on the May 2004 human reference sequence (NCBI Build 35).
†'NEAR' means within 60 kb to a gene; 'IN' means within a gene.
†† The p-values are from the GEE association test on multivariable adjusted phenotypes listed below.Page 9 of 11
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cell.
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